カテゴリ： GlobalData, 中国, 企業調査

Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196)：製薬・医療：M&Aディール及び事業提携情報

◆英語タイトル：Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード：DATA904C7615
◆発行会社（調査会社）：GlobalData
◆発行日：2018年10月
◆ページ数：109
◆レポート言語：英語
◆レポート形式：PDF
◆納品方法：Eメール
◆対象地域：中国
◆産業分野：製薬・医療
◆販売価格オプション（消費税別）
Single User（1名様閲覧用）USD250 ⇒換算￥37,000見積依頼/購入/質問フォーム
Site License（同一事業所内共有可）USD500 ⇒換算￥74,000見積依頼/購入/質問フォーム
Enterprisewide License（複数事業所内共有可）USD750 ⇒換算￥111,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※本体価格が￥30,000未満のレポートにつきましては、ハンドリングチャージ￥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
※GlobalData社の概要はこちらでご確認いただけます。

このエントリーをはてなブックマークに追加
LINEで送る


【レポートの概要】

Summary
Shanghai Fosun Pharmaceutical (Group) Co Ltd (Fosun Pharma), a subsidiary of Shanghai Fosun High Technology (Group) Co Ltd is a drug company that offers pharmaceutical products, medical diagnostic products and medical device products. The company’s pharmaceutical products include metabolism and digestive system, cardiovascular system, blood system, central nervous system drugs, anti-infection, anti-tumor, vaccine and raw material and intermediates. It provides medical diagnostic products such as real time PCR detector, human papillomavirus assay kit, HBV quantitative reagent, and biofosun microorganism identification and susceptibility analysis system. The company’s research and development unit concentrates on therapeutic areas of metabolism and digestive system, blood system, cardiovascular system and central nervous system. Fosun Pharma is headquartered in Shanghai City, Shanghai, China.

Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 6
List of Figures 7
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deal Details 19
Asset Purchase 19
Novartis May Sell US Generic Pill Business 19
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 21
Venture Financing 22
Ambrx Raises USD45 Million in Venture Financing 22
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 24
Private Equity 26
KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 26
Partnerships 27
AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 27
Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 28
Marubeni to Form Joint Venture with Shanghai Fosun Pharma 29
Kite Pharma Forms Joint Venture with Fosun Pharma 30
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 31
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 32
Nature’s Sunshine Products Forms Joint Venture with Fosun Pharma 33
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 34
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 35
Atrium Innovations Forms Joint Venture With Fosun Industrial 36
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 37
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 38
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 39
Licensing Agreements 40
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial – Portela 40
Athenex to Enter into Licensing Agreement with Gland Pharma 41
Athenex to Enter into Licensing Agreement with Gland Pharma 42
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 43
Sirona Biochem Enters into Licensing Agreement with Wanbang Biopharma for SGLT2 Inhibitor 44
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 46
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 47
Equity Offering 48
Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 48
Gland Pharma May Raise USD500 Million in IPO 50
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 51
Chindex to Raise USD38.2 Million in Private Placement of Shares 53
Phagelux Raises Funds through Private Placement 54
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 55
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 56
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 57
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 58
Nature’s Sunshine Raises USD46 Million in Private Placement of Shares 59
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 61
Debt Offering 62
Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 62
Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 63
Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 64
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 65
Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 66
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 67
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 68
Asset Transactions 69
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 69
Acquisition 70
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 70
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 71
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 73
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 74
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 76
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 77
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 78
Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For US$426.4 Million 79
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 83
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 86
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Key Competitors 87
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Key Employees 88
Shanghai Fosun Pharmaceutical (Group) Co Ltd – Locations And Subsidiaries 90
Head Office 90
Other Locations & Subsidiaries 90
Recent Developments 91
Strategy And Business Planning 91
Nov 15, 2017: Fosun Pharma set up Suzhou R & D Center 91
Jul 11, 2017: Rooted in Shanghai innovation Fosun Pharma Zhangjiang new R & D headquarters base was officially launched 92
Financial Announcements 94
Mar 27, 2018: Fosun pharma: Announcement of Final Results for the Year Ended 31 December 2017 94
Oct 31, 2017: Fosun Pharma releases third quarter 2017 revenue up 21.83% YoY Research and development investment continues to increase 96
Aug 30, 2017: Fosun Pharma: R & D and international lighting performance, the first half revenue grew 20.41% 97
Jun 14, 2017: Fosun Pharma released first quarter 2017 revenue up 20.29% R & D investment continued to increase 99
Mar 31, 2017: Fosun Pharma non-net profit in 2016 increased by 26.36% year-on-year Continued to increase innovation and R & D investment Strengthen the layout of medical services 100
Corporate Communications 103
Mar 26, 2018: Change In Fosun Pharma’s Board Of Directors To Further Align Group Strategy 103
Mar 26, 2018: Shanghai Fosun Pharmaceutical Announces Personnel Changes 104
Sep 05, 2017: Fosun Pharmas Subsidiary Sisram, the World’s Leading Energy-Based Medical Aesthetic Treatment Systems Provider, to be Listed as the First Israeli Company on the Main Board of SEHK 106
Product Approvals 108
Oct 29, 2017: Fosun Pharma treatment of leukemia new drug approved by the FDA drug clinical trials 108
Appendix 109
Methodology 109
About GlobalData 109
Contact Us 109
Disclaimer 109

List of Tables
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 11
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 14
Novartis May Sell US Generic Pill Business 19
Shanghai Fosun Pharma Plans to Acquire Medicine Products from Sandoz for USD18 Million 21
Ambrx Raises USD45 Million in Venture Financing 22
Saladax Biomedical Raises US$23 Million In Series D Venture Financing 24
KKR Receives Government Approval To Acquire 35% Stake In Gland Pharma For USD200 Million 26
AkaRx Enters into Distribution Agreement with Shanghai Fosun Pharma 27
Shanghai Fosun Pharma Plans to Form Joint Venture with Fosun International 28
Marubeni to Form Joint Venture with Shanghai Fosun Pharma 29
Kite Pharma Forms Joint Venture with Fosun Pharma 30
Breckenridge Pharma Enters into Marketing Agreement with Gland Pharma 31
Dr. Reddy’s Labs Enters into Co-Marketing Agreement with Gland Pharma 32
Nature's Sunshine Products Forms Joint Venture with Fosun Pharma 33
Miacom Diagnostics Enters into Co-Marketing Agreement with Fosun Diagnostics 34
Maxigen Biotech Enters into Agreement with Shanghai Fosun Pharma 35
Atrium Innovations Forms Joint Venture With Fosun Industrial 36
Shanghai Fosun Enters Into Joint Venture With Dalian Wanchun To Develop Oncology Treatments 37
Biotest Enters Into Distribution Agreement With Wanbang Biopharma For Human Serum Albumin 38
Shanghai Fosun Pharma Enters Into Co-Development Agreement With Shanghai Institute of Materia Medica To Develop Cancer Drug 39
Jiangsu Wanbang Biochemical Enters into Licensing Agreement with Bial - Portela 40
Athenex to Enter into Licensing Agreement with Gland Pharma 41
Athenex to Enter into Licensing Agreement with Gland Pharma 42
Shanghai Fosun Pharma Enters into Licensing Agreement with LegoChem Biosciences 43
Sirona Biochem Enters into Licensing Agreement with Wanbang Biopharma for SGLT2 Inhibitor 44
TB Alliance Enters Into Licensing Agreement With Fosun Pharma 46
Shenzhen Salubris Pharma Enters Into Licensing Agreement With Shanghai Fosun Pharma For Diabetes Drug 47
Shanghai Fosun Pharma Raises USD331 Million in Private Placement of Shares 48
Gland Pharma May Raise USD500 Million in IPO 50
Shanghai Fosun Pharma to Raise USD298.3 Million in Private Placement of Shares 51
Chindex to Raise USD38.2 Million in Private Placement of Shares 53
Phagelux Raises Funds through Private Placement 54
Shanghai Fosun Pharma Decreases Size of Private Placement of Shares for USD376 Million 55
Shanghai Fosun Pharma Raises USD940 Million in Private Placement of Shares 56
Shanghai Fosun Pharma to Raise Funds through Private Placement of Shares 57
Amerigen Pharma to Raise USD35 Million in Private Placement of Shares 58
Nature's Sunshine Raises USD46 Million in Private Placement of Shares 59
Shanghai Fosun Pharma Prices Private Placement Of Shares For US$229.6 Million 61
Shanghai Fosun Pharma Raises USD190.7 Million in Public Offering of 5.1% Bonds Due 2023 62
Shanghai Fosun Pharma to Raise USD791 Million in Public Offering of Bonds 63
Amerigen Pharma to Raise USD10 Million in Private Placement of 15% Bonds Due 2020 64
Shanghai Fosun Pharma Plans to Raise up to USD1 Billion in Private Placement of Bonds 65
Shanghai Fosun Pharma Raises USD339.3 Million in Private Placement of Shares 66
Shanghai Fosun Pharma to Raise USD459 Million in First Tranche Public Offering of Bonds Due 2021 67
Shanghai Fosun Pharma Raises USD65.3 Million in First Tranche of Private Placement of 3.95% Notes Due 2018 68
Sinopharm Plans to Acquire Pharmacy Business from Shanghai Fosun Pharma 69
Shanghai Fosun Pharma to Acquire 69.3% Stake in Henlix Biotech for USD98 Million 70
Shanghai Fosun Pharma Acquires 74% Stake in Gland Pharma for USD1.1 Billion 71
Shanghai Fosun Pharma to Acquire 2.6% Stake in Jinzhou Austrian Hong Pharma for USD26 Million 73
Shanghai Fosun Pharma, HOPU Investments, CEL Healthcare Fund and WuXi PharmaTech to Acquire Ambrx 74
Shanghai Fosun Pharma Plans to Acquire 65% Stake in Suzhou Erye for USD137 Million 76
Sinopharm Plans to Acquire Three Pharmacies from Shanghai Fosun Pharma for USD67 Million 77
Shanghai Fosun Pharma To Acquire Additional 28% Stake In Jinzhou Aohong Pharma For Up To US$304 Million 78
Winteam Pharma Completes Acquisition Of Tongjitang Chinese Medicines From Hanmax And Fosun International For US$426.4 Million 79
Fosun Pharma Acquires 50% Stake In Guangzhou Nanyang Tumour Hospital 81
Wanbang Biopharma Acquires 51% Stake In Zaozhuang Sainuokang 82
Shanghai Fosun Pharma Completes Acquisition Of 77.78% Stake In Hunan Dongting Pharma For US$93 Million 83
Shanghai No. 1 Pharmacy Plans To Acquire 50% Stake In Shanghai-Based Chain Pharmacy Company 84
Shanghai Fosun Pharma Completes Acquisition Of 55% Stake In Zhongwu Hospital 85
Fosun Pharma Acquires 11% Stake In Shenzhen Belter For US$7 Million 86
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Competitors 87
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Key Employees 88
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Subsidiaries 90

List of Figures
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 8
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 9
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 10
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 11
Shanghai Fosun Pharmaceutical (Group) Co Ltd, Medical Devices Deals, 2012 to YTD 2018 13

★海外企業調査レポート[Shanghai Fosun Pharmaceutical (Group) Co Ltd (600196)：製薬・医療：M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら
■おすすめ企業レポート■
  • Serinus Energy Plc (SEN)：石油・ガス：M&Aディール及び事業提携情報
    Summary Serinus Energy Plc (Serinus), formerly Serinus Energy Inc is an oil and gas company that explores and produces oil and natural gas products. The company explores, acquires and develops crude oil and natural gas reserves. It holds 100% interest in Satu Mare Concession located in the Eastern P …
  • Kaiser Foundation Health Plan of Washington：企業の戦略的SWOT分析
    Kaiser Foundation Health Plan of Washington - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors a …
  • The Madison Square Garden Co：企業の戦略・SWOT・財務情報
    The Madison Square Garden Co - Strategy, SWOT and Corporate Finance Report Summary The Madison Square Garden Co - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Banca IFIS SpA：企業の戦略・SWOT・財務情報
    Banca IFIS SpA - Strategy, SWOT and Corporate Finance Report Summary Banca IFIS SpA - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpora …
  • SandRidge Energy Inc (SD)：企業の財務・戦略的SWOT分析
    SandRidge Energy Inc (SD) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses …
  • Credit Saison Co., Ltd.：企業の戦略・SWOT・財務分析
    Credit Saison Co., Ltd. - Strategy, SWOT and Corporate Finance Report Summary Credit Saison Co., Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Essar Power Limited：電力：M&Aディール及び事業提携情報
    Summary Essar Power Limited (Essar Power) a subsidiary of Essar Energy Limited, is an electric utility. It produces electricity and thermal energy. The company generates power from naphtha, high-speed diesel, coal, natural gasoline liquid, and natural gas sources. Essar Power owns and operates co-ge …
  • Workspace Group Plc：企業の戦略・SWOT・財務情報
    Workspace Group Plc - Strategy, SWOT and Corporate Finance Report Summary Workspace Group Plc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Ultrastroy Eood：企業の戦略的SWOT分析
    Ultrastroy Eood - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Clean Diesel Technologies Inc (CDTI)：企業の財務・戦略的SWOT分析
    Summary Clean Diesel Technologies Inc (CDTI) is a clean technology company that manufactures and distributes heavy duty diesel and light duty vehicle emissions control systems and products to automakers and retrofitters. The company's products include catalyst products, heavy duty diesel products, a …
  • Medusa Mining Ltd：企業の戦略・SWOT・財務分析
    Medusa Mining Ltd - Strategy, SWOT and Corporate Finance Report Summary Medusa Mining Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and c …
  • Driver Group Plc (DRV)：企業の財務・戦略的SWOT分析
    Driver Group Plc (DRV) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Petroleo Brasileiro SA (PETR4)：企業の財務・戦略的SWOT分析
    Petroleo Brasileiro SA (PETR4) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • ORBIT Communication Systems Ltd：企業の戦略・SWOT・財務情報
    ORBIT Communication Systems Ltd - Strategy, SWOT and Corporate Finance Report Summary ORBIT Communication Systems Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product …
  • Assembly Biosciences Inc (ASMB)-製薬・医療分野：企業M&A・提携分析
    Summary Assembly Biosciences Inc (Assembly), formerly Ventrus Biosciences Inc is a biotechnology company that discover, develops and commercializes small molecule therapies. The company develops therapies for the treatment of infectious diseases such as chronic hepatitis B virus (HBV) and microbioti …
  • Treet Corporation Ltd (TREET)：企業の財務・戦略的SWOT分析
    Treet Corporation Ltd (TREET) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakne …
  • aTyr Pharma Inc (LIFE)：企業の財務・戦略的SWOT分析
    Summary ATyr Pharma Inc (ATyr Pharma) is a clinical-stage biotechnology company engaged in the discovery and clinical development of medicines for the treatment of cancer and lung diseases. The company’s ATYR1923 is a clinical-stage product candidate, based on the resokine pathway, which binds to th …
  • Par Pacific Holdings, Inc. (PARR)-石油・ガス分野：企業M&A・提携分析
    Summary Par Pacific Holdings, Inc. (Par Pacific), formerly known as Par Petroleum Corporation, manages, owns and maintains interests in energy and infrastructure related businesses. It has operations across the value chain from natural gas production to distribution and transportation. The company c …
  • Isagen SA ESP：企業の発電所・SWOT分析2018
    Isagen SA ESP - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key employees (exec …
  • ProterixBio Inc：医療機器：M&Aディール及び事業提携情報
    Summary ProterixBio Inc (ProterixBio), formerly BioScale Inc, is a medical device company that manufactures and markets ViBE platform products. The company offers ViBE platform, acoustic assays, ViBE software and custom assays, among others. Its ViBE platform enables non-optical detection and sensit …

◆H&Iグローバルリサーチ株式会社のお客様（例）◆